Blog Posts

Breaking News

Two of Three Appeals Court Judges Question Government’s Stance That Drug Companies May Not Impose Conditions on 340B Sales

U.S. Third Circuit Court of Appeals
Two judges on a three-judge federal appeals court panel in Philadelphia today questioned whether the 340B statute forbids drug manufacturers from imposing distribution conditions on offers of 340B pricing.

Two judges on a three-judge federal appeals court panel this morning challenged a federal government lawyer’s stance that federal law forbids drug manufacturers from limiting how their drugs may be distributed when they offer to sell the drugs

Read More »

Appeals Court To Hear Arguments Today in AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Suits

U.S. Third Circuit Court of Appeals
A federal appeals court in Philadelphia is hearing arguments today in AstraZeneca, Novo Nordisk, and Sanofi’s 340B contract pharmacy lawsuits.

A federal appeals court in Philadelphia this morning is hearing arguments in AstraZeneca, Novo Nordisk, and Sanofi’s lawsuits challenging federal agency findings that the drug companies’ 340B contract pharmacy policies are illegal and must stop or the firms

Read More »

Hospital Group Says Survey Shows Drug Companies’ 340B Contract Pharmacy Limits Are Harmful

AHA survey
Drug companies' 340B contract pharmacy limits are harming 340B hospitals and their patients, the AHA says a new member survey shows.

Drug company actions to limit 340B pricing through contract and specialty pharmacies are harming 340B hospitals and their patients, according to a new American Hospital Association member survey.

Please Login or Become a Paid

Read More »

With Democrats Retaining Control of U.S. Senate, Expect New Leadership in Key Committee

Election
Democrats will still control the U.S. Senate for the next two years, but party control of the House had not yet been determined as of early this morning.

Democrats will still control the U.S. Senate for the next two years, it became clear over the weekend, but control of the House has not yet been decided one week after the Nov. 8 midterm elections.

Read More »

340B Law Should Be Amended to Include Emergency-Use COVID-19 Drugs, Health Affairs Opinion Article Says

Bebtelovimab
A screen shot from an HHS video about the monoclonal antibody betelovimab used to treat COVID-19 infection.

The 340B statute should be amended to extend discounts to emergency-use drugs to treat COVID-19 as a first step in rebuilding the COVID-19 safety net, an opinion piece published yesterday in the medical journal Health Affairs says.

Read More »

Fake Lilly Twitter Account Tweets “Insulin Is Free Now,” Temporarily Wiping Billions From Company’s Stock Value

Counterfeit insulin tweet
On Friday, a counterfeit Eli Lilly account bearing a checkmark that caused many to believe the account was authentic tweeted, “We are excited to announce insulin is free now," causing havoc.

The havoc caused by Twitter’s new policy on user identity verification struck drug manufacturer Eli Lilly last week when a counterfeit account bearing one of Twitter’s new $8 checkmarks tweeted, “We are excited to announce insulin is free

Read More »

With Party Control of Congress Still Undecided, 340B Providers Lose Some Key Champions but Retain Some Heavy Hitters

Cathy McMorris Rodgers
Rep. Cathy McMorris Rodgers (R-Wash.) is in line to be the new House Energy & Commerce Committee chair if Republicans capture the majority in the still undecided midterm elections.

Partisan control of Congress for the final two years of President Biden’s term in office was still undecided this morning, two days after Tuesday’s mid-term elections.

Please Login or Become a Paid Subscriber to

Read More »

MedPAC Is Expected to Make a Policy Recommendation That Could Prompt a Look at 340B Hospital Program Eligibility Criteria

MedPAC
MedPAC is on track to make a recommendation to Congress that could prompt debate or even action on the 340B program’s use of the Medicare disproportionate share (DSH) patient percentage to determine hospital eligibility.

Congressional Medicare advisers are moving toward recommending what they say is a better way to give extra Medicare funding to safety-net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.

Please Login or Become a

Read More »

340B Pricing: Navigating Pharmacy Discount Programs to Benefit Your Entity & Patients

Jim Donnelly, Hudson Headwaters 340B

SPONSORED CONTENT

The 340B statute was written as a drug pricing program that outlines specifically what manufacturers are required to charge qualified covered entities for their drugs based on a defined formula. The intent of the 340B program is to help these safety net entities stretch their scarce resources to maintain and enhance services

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report